mPOD, Inc. (New York, NY) is developing a rapid-response POC diagnostics platform that leverages aptamers for the detection of biomarkers for infectious and emerging diseases. Our core competency is integrating aptamer design and development into a biosensor platform for detecting pathogens in biofluids. The mPOD COVID-19 Dx is simple and affordable, requiring no special equipment or skills to administer. mPOD, Inc. is supported by the NIH, Cornell McGovern Center, and is a BARDA-JLABS Blue Knight company.